These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 14756852)

  • 1. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation.
    Fox AW
    Headache; 2004 Feb; 44(2):142-7. PubMed ID: 14756852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of absorption rate and lag time to the onset of action in migraine.
    Maas HJ; Spruit MA; Danhof M; Della Pasqua OE
    Clin Pharmacokinet; 2008; 47(2):139-46. PubMed ID: 18193920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of intranasal sumatriptan.
    Fuseau E; Petricoul O; Moore KH; Barrow A; Ibbotson T
    Clin Pharmacokinet; 2002; 41(11):801-11. PubMed ID: 12190330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers.
    Walls C; Lewis A; Bullman J; Boswell D; Summers SJ; Dow A; Sidhu J
    Curr Med Res Opin; 2004 Jun; 20(6):803-9. PubMed ID: 15200736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients.
    Cosson VF; Fuseau E
    J Pharmacokinet Biopharm; 1999 Apr; 27(2):149-71. PubMed ID: 10567953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of concentration-response differences in onset of effect between subcutaneous and oral sumatriptan.
    Freidank-Mueschenborn E; Fox AW
    Headache; 2005 Jun; 45(6):632-7. PubMed ID: 15953294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
    Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA
    Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.
    Duquesnoy C; Mamet JP; Sumner D; Fuseau E
    Eur J Pharm Sci; 1998 Apr; 6(2):99-104. PubMed ID: 9795022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
    Tfelt-Hansen P; De Vries P; Saxena PR
    Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of new therapeutic deliveries in migraine.
    Dahlöf C
    Neurology; 2003 Oct; 61(8 Suppl 4):S31-4. PubMed ID: 14581656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sumatriptan. An updated review of its use in migraine.
    Perry CM; Markham A
    Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.
    Ferrari A; Pinetti D; Bertolini A; Coccia C; Sternieri E
    Eur J Clin Pharmacol; 2008 May; 64(5):489-95. PubMed ID: 18180912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sumatriptan fast-disintegrating/rapid-release tablets: viewpoints.
    Carpay HA; Dowson AJ
    Drugs; 2006; 66(6):891-2. PubMed ID: 16706566
    [No Abstract]   [Full Text] [Related]  

  • 18. Transdermal delivery of sumatriptan for the treatment of acute migraine.
    Pierce MW
    Neurotherapeutics; 2010 Apr; 7(2):159-63. PubMed ID: 20430314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan.
    Siegel SJ; O'Neill C; Dubé LM; Kaldeway P; Morris R; Jackson D; Sebree T
    Pharm Res; 2007 Oct; 24(10):1919-26. PubMed ID: 17577644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.
    Tfelt-Hansen P
    J Headache Pain; 2007 Oct; 8(5):273-6. PubMed ID: 17955173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.